Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
08:52pm, Tuesday, 03'rd Mar 2026
Halozyme Therapeutics, Inc. (HALO) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Halozyme to Participate in Upcoming Investor Conferences
08:30am, Wednesday, 25'th Feb 2026
SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present a
Can AST SpaceMobile's HALO Contract Strengthen Its Defense Footprint?
12:36pm, Tuesday, 24'th Feb 2026
ASTS lands a $30 million Space Development Agency contract to deploy BlueBird LEO satellites, advancing direct-to-device defense communications.
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment
AST SpaceMobile Awarded $30 Million Prime Contract by U.S. Space Development Agency for HALO Europa Program
11:20am, Monday, 23'rd Feb 2026
MIDLAND, Texas--(BUSINESS WIRE)---- $ASTS #AST--AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible
Halozyme Therapeutics Q4 Earnings Call Highlights
04:06am, Thursday, 19'th Feb 2026
Halozyme Therapeutics (NASDAQ: HALO) executives highlighted what they described as a "significant and value-creating" 2025, pointing to accelerating royalty growth from ENHANZE-enabled products, expan
Halozyme Therapeutics (NASDAQ:HALO) Trading Down 8.7% on Disappointing Earnings
01:59am, Thursday, 19'th Feb 2026
Halozyme Therapeutics, Inc. (NASDAQ: HALO - Get Free Report)'s stock price dropped 8.7% during trading on Wednesday following a weaker than expected earnings announcement. The company traded as low as
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
12:20pm, Wednesday, 18'th Feb 2026
HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.
Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge
10:02am, Wednesday, 18'th Feb 2026
Halozyme Therapeutics is entering a powerful earnings inflection, driven by surging royalty revenue and strategic acquisitions expanding its drug delivery platform. FY25 revenue grew 38% to $1.397 bil
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
08:24pm, Tuesday, 17'th Feb 2026
Halozyme Therapeutics, Inc. (HALO) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings
07:30pm, Tuesday, 17'th Feb 2026
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wal
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
06:10pm, Tuesday, 17'th Feb 2026
Halozyme Therapeutics (HALO) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of $2.15. This compares to earnings of $1.26 per share a year ago.
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
04:01pm, Tuesday, 17'th Feb 2026
Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Techn
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
10:51am, Monday, 16'th Feb 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics
10:16am, Friday, 13'th Feb 2026
Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of i
